• Publications
  • Influence
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.
BACKGROUND & AIMS Chronic liver diseases (CLDs) are major causes of morbidity and mortality worldwide. We assessed changes in the prevalence of different types of CLD in the United States. METHODSExpand
  • 775
  • 19
Long-term follow-up of patients with nonalcoholic fatty liver.
BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of conditions ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) convincingly. NASH isExpand
  • 575
  • 13
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
AbstractThe presence of hepatic steatosis in individuals without a known cause of chronic liver disease, including excessive alcohol consumption, is the hallmark of nonalcoholic fatty liver diseaseExpand
  • 299
  • 8
The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis.
BACKGROUND AND AIMS Although Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH) and NASH with advanced fibrosis are closely associated with type 2 diabetes mellitusExpand
  • 137
  • 8
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. We investigated factors associated with advanced fibrosis in NAFLD. METHODS The study includedExpand
  • 197
  • 5
Vietnamese community screening for hepatitis B virus and hepatitis C virus
Summary.  Asian Americans represent an important cohort at high risk for viral hepatitis. To determine the prevalence of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infection and HBVExpand
  • 28
  • 3
Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors
To compare physical activity levels and dietary choices of patients who have chronic hepatitis C (CHC) with those of blood donors (BDs).
  • 5
  • 1
A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment
Summary.  Dose reductions of pegylated interferon alpha and ribavirin may be avoided by using growth factors. This phase II clinical trial assesses the dose, efficacy and safety of darbepoetin alphaExpand
  • 43
Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity
Summary.  Studies from tertiary care medical centres have linked hepatitis C virus (HCV) to the development of insulin resistance (IR) and type 2 diabetes. The aim of the study is to assess theExpand
  • 53
Inpatient Economic and Mortality Assessment for Liver Transplantation: A Nationwide Study of the United States Data From 2005 to 2009
Background Liver transplantation is a standard of care for treatment of end-stage liver disease. The aim of this study was to evaluate resource utilization for patients admitted to the U.S. hospitalsExpand
  • 18